HBM Holdings Past Earnings Performance
Past criteria checks 2/6
HBM Holdings has been growing earnings at an average annual rate of 31.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 66.6% per year. HBM Holdings's return on equity is 17.3%, and it has net margins of 29.5%.
Key information
31.7%
Earnings growth rate
59.0%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 66.6% |
| Return on equity | 17.3% |
| Net Margin | 29.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump
Oct 02
Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet
Jul 18HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly
May 23Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper
Apr 12HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Jan 01We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate
Feb 08HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business
May 30Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)
Apr 07Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results
Mar 31What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?
Mar 10Revenue & Expenses Breakdown
How HBM Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 72 | 21 | 22 | 30 |
| 31 Mar 24 | 81 | 22 | 21 | 37 |
| 31 Dec 23 | 90 | 23 | 21 | 45 |
| 30 Sep 23 | 72 | -19 | 21 | 62 |
| 30 Jun 23 | 54 | -61 | 21 | 80 |
| 31 Mar 23 | 47 | -99 | 24 | 108 |
| 31 Dec 22 | 41 | -137 | 27 | 135 |
| 30 Sep 22 | 35 | -143 | 35 | 142 |
| 30 Jun 22 | 30 | -149 | 43 | 150 |
| 31 Mar 22 | 17 | -144 | 42 | 128 |
| 31 Dec 21 | 4 | -138 | 40 | 107 |
| 30 Sep 21 | 7 | -224 | 46 | 94 |
| 30 Jun 21 | 10 | -310 | 53 | 81 |
| 31 Mar 21 | 12 | -303 | 50 | 68 |
| 31 Dec 20 | 14 | -296 | 46 | 55 |
| 30 Sep 20 | 13 | -187 | 28 | 46 |
| 30 Jun 20 | 11 | -78 | 11 | 37 |
| 31 Mar 20 | 8 | -73 | 11 | 43 |
| 31 Dec 19 | 5 | -67 | 11 | 49 |
| 31 Dec 18 | 1 | -35 | 6 | 32 |
Quality Earnings: 2142 has a high level of non-cash earnings.
Growing Profit Margin: 2142 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2142 has become profitable over the past 5 years, growing earnings by 31.7% per year.
Accelerating Growth: 2142 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 2142 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).
Return on Equity
High ROE: 2142's Return on Equity (17.3%) is considered low.